PRESS RELEASE

Krka Reports January to September 2026 Business Results

Novo mesto
12 November 2026

From January to September 2026, the Krka Group generated revenue of €1,660 million, up 8% year on year, yielding €364.2 million net profit, a 13% increase on the same period last year. The Supervisory Board of Krka discussed the January to September 2026 interim report for the Krka Group and Krka, d. d., at its regular meeting yesterday.

President of the Management Board and Chief Executive Officer Jože Colarič stated on the occasion: 'The Krka Group's successful business performance continued in the third quarter of this year. We increased product and service sales in five sales regions and most of our markets. Revenue amounted to €1,660 million, an 8% year-on-year increase. All our key business performance measures also increased. EBITDA increased by 21% to €527.9 million, while EBITDA margin reached 31.8%. EBIT totalled €455.5 million, up 24% year on year, while net profit surpassed €364 million, a 13% increase on the same period last year.

The achieved results demonstrate that we have been successfully implementing our long-term strategy founded on in-house development, innovation, operational excellence, and the ability to respond quickly to changes in the international environment. We earmarked €87.3 million for investments, a 31% year-on-year increase, and allocated 9.1% of revenue to research and development, which places us among the most research-intensive generic pharmaceutical companies. The continued roll-out of our new products and life-cycle management of existing products help us strengthen our competitiveness and enhance product availability. We added ten new products to our diverse product portfolio, which serves as the foundation for our long-term stable growth and good business results.

Considering our performance in the first three quarters, we expect to surpass our 2026 targets and create revenue of €2,179 million and net profit of €439 million. We have also informed the Supervisory Board on our 2027 business plan. The plan projects a further increase in revenue, reaching €2,308 million, and net profit of €474 million. The performance estimate and the business plan agree with the long-term *Krka Group Development Strategy*.'

Krka Group highlights

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Revenue	1,660,036	1,534,028	108
– Of which revenue from sales of products and services	1,652,775	1,529,127	108
Gross profit	1,009,859	884,852	114
Earnings before interest, tax, depreciation and amortisation (EBITDA)	527,942	436,734	121
Operating profit (EBIT)	455,531	367,154	124
Profit before tax (EBT)	451,088	395,453	114
Net profit	364,221	323,654	113
R&D expenses	150,457	143,733	105
Investments	87,322	66,742	131

Krka Group performance ratios


	Jan–Sep 2026	Jan–Sep 2025
Gross profit margin	60.8%	57.7%
EBITDA margin	31.8%	28.5%
EBIT margin	27.4%	23.9%
EBT margin	27.2%	25.8%
Net profit margin (ROS)	21.9%	21.1%
Return on equity (ROE)	20.2%	19.0%
Return on assets (ROA)	15.8%	14.8%
Liabilities/Equity	0.272	0.287
R&D expenses/Revenue	9.1%	9.4%

Krka Group sales

Product and service sales by region

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Region Slovenia	104,097	98,821	105
Region South-East Europe	235,583	218,220	108
Region East Europe	606,731	533,723	114
Region Central Europe	374,315	350,857	107
Region West Europe	266,805	272,389	98
Region Overseas Markets	65,244	55,117	118
Total	**1,652,775**	**1,529,127**	**108**

January–September 2026 product and service sales by region



The figures in parentheses show year-on-year changes in sales by region.

Region East Europe generated €606.7 million in product sales and was the largest sales region in the Krka Group. Product sales totalled €372.1 million in the Russian Federation, our largest individual market by sales value, up 18% on last year. In Ukraine, product sales reached €82.7 million, up 14% on the same period last year. We recorded sales growth in all other markets of eastern Europe and central Asia, except in Uzbekistan and Turkmenistan.

Region Central Europe, our next largest sales region, recorded product sales of €374.3 million. Product sales in Poland, our second largest individual market by sales value, reached €187.1 million, a 5% year-on-year increase. Product sales amounted to €51.5 million (up 7%) in Czechia, and €45.6 million (up 15%) in Hungary. Sales also increased in all other regional markets.

Generating €266.8 million, Region West Europe was the third region for sales. In Germany, the largest regional market by sales value, product sales amounted to €65.6 million, up 1% year on year. Our regional sales saw the highest increases in Portugal (up 4%), Ireland (up 3%), and Austria (up 3%).

Region South-East Europe generated €235.6 million in product sales. We increased sales in all regional markets. In Romania, product sales totalled €59.3 million, up 1% year on year.


Product and service sales in Region Slovenia totalled €104.1 million. According to the latest available data for the period from January to September of 2026, we retained the leading position among pharmaceutical providers, holding a 7.4% share of the Slovenian market.

Region Overseas Markets increased sales primarily on the back of sales growth in the Far East and Africa.

Product and service sales by group

€ thousand	Jan–Sep 2026	Jan–Sep 2025	Index
Human health products	1,515,880	1,398,379	108
– Prescription pharmaceuticals	1,396,566	1,274,060	110
– Non-prescription products	119,314	124,319	96
Animal health products	94,976	88,830	107
Health resort and tourist services	41,919	41,918	100
Total	**1,652,775**	**1,529,127**	**108**

January–September 2026 product and service sales by group



The figures in parentheses show year-on-year changes in product and service sales by group.

Research and development

In the first nine months of 2026, we expanded our product range with ten new products, including nine new prescription pharmaceuticals and one new veterinary medicine for companion animals. We finalised over 500 registration procedures for new and already established products in several markets.

We obtained first marketing authorisations for two single-pill antidiabetic combinations, Mempoglyn (empagliflozin/metformin) and Lymerexa (linagliptin/metformin). The two agents in film-coated tablets combine two active substances with synergistic modes of action, providing a modern and comprehensive approach to the treatment of type 2 diabetes, and allowing for patient-tailored therapies. We expanded our cardiovascular portfolio by obtaining marketing authorisations for Co-Pitavador (pitavastatin/ezetimibe), a single-pill combination indicated for treatment of patients with combined hyperlipidaemia. In one of our key therapeutic areas, central nervous system diseases, marketing authorisation was granted for Acazanian (cariprazine) hard capsules, a new medicine used to treat schizophrenia. Marketing authorisations were also granted for two reformulated medicines: Asentra (sertraline) film-coated tablets used to treat depression and anxiety disorders and Dulsevia (duloxetine) gastro-resistant capsules, in some countries marketed as Loxentia, used in various therapeutic areas, but primarily for treating mental health conditions such as depression and anxiety and relieving peripheral diabetic neuralgia in adults. We obtained marketing authorisations for our two new cardiovascular agents in China, bisoprolol/amlodipine combination tablets and edoxaban film-coated tablets. A marketing authorisation was granted for a new strength of the single-pill combination of empagliflozin and metformin film-coated tablets used to treat diabetes, tailored to the needs of the Chinese market.

We expanded the range of animal health products for companion animals with marketing authorisations for our new product Robexera (robenacoxib) chewable tablets for cats, marketed as Rogiola in certain countries. It is indicated for the control of pain and inflammation associated with musculoskeletal diseases and for the relief of moderate pain and inflammation after surgery.

Investments

In the first nine months of 2026, the Krka Group allocated €87.3 million to investments, of which €68.3 million was allocated to the controlling company.

The upgrades at the Notol plant in Novo mesto, Slovenia, are designed to ensure reliable operations over the next 20 years. We plan to expand production capacity by constructing an extension to the solid dosage production plant. We successfully carried out preparations for the logistics system upgrade due for completion in 2027. We also intend to increase production capacity by installing additional equipment at Notol 2, another production plant in Novo mesto.

We completed the investment in additional capacities for tabletting mixture preparation, granulation, and logistics at the Solid Dosage Products Plant in Novo mesto and launched a new project to increase production output and enhance manufacturing flexibility.

We installed a new suspension inspection line and finished building an extension for a new production line for sterile solutions at the Sterile Products Department in Novo mesto, thereby significantly enhancing production volumes.

At the Ločna site, we completed equipping the newly constructed seven-storey multi-purpose building and obtained the occupancy permit.

Work is in progress at the Baršljin Department in Novo mesto, Slovenia, to increase the production and packaging capacities for products for veterinary use. We also expect to boost the capacity for packaging tablets for veterinary use and spot-on solutions in the existing facility.

We increased the production capacity at the Ljutomer plant in Slovenia. Construction of an automated high-bay warehouse and an expansion of the plant are under way.

We completed construction of the technically and technologically advanced waste water treatment plant in Krško, Slovenia. Pre-treatment has been in operation since September. We also commissioned the remaining phases of the biological treatment process, and the plant is currently in trial operation.

We are currently increasing production capacity at the production and distribution centre in Jastrebarsko, Croatia.

In China, we set up product manufacturing operations to support the animal health programme. A filling and packaging line was installed and qualified.

Construction of research and production facilities for oncology products and solid dosage forms is underway at Krka Pharma Private Limited, a joint venture in Hyderabad, India.

Employees

At the end of September 2026, the Krka Group employed 13,307 persons, of whom 5,539 or 42% worked outside Slovenia. Of all Krka Group employees, 48% held at least a university degree, while 207 held doctoral degrees.

Investor and share information

The Krka share price on the Ljubljana Stock Exchange rose by 27% in the first nine months of 2026 and stood at €258.50 on 30 September 2026. During this period, holdings of Slovenian retail investors, legal entities and institutional investors, as well as treasury shares, increased, while foreign investor holdings declined. At the end of September 2026, Krka had 50,269 shareholders.

As at 30 September 2026, Krka's market capitalisation on the Ljubljana Stock Exchange, including treasury shares, totalled €8.5 billion. The average daily trading volume of Krka shares during the period amounted to €1.2 million.

In the first nine months of 2026, Krka acquired 127,978 treasury shares and held 2,562,805 treasury shares as at 30 September 2026, accounting for 7.815% of share capital.

2026 Krka Group performance estimate

- Full-year revenue is projected at €2,179 million, up 7% year on year. Estimated revenue exceeds the 2026 revenue target.
- The share of sales generated outside Slovenia is estimated at 94%.
- Prescription pharmaceuticals are set to remain the leading product category, accounting for 84% of total sales.
- Net profit is forecast at €439 million, up 9% year on year, outstripping the 2026 plan by €34 million.
- We plan to invest just under €115 million in in-house development, production, and infrastructure facilities, a €20 million increase on 2025.
- At the end of 2026, the Krka Group is expected to have 13,443 regular employees on payroll, up 2% year on year, of whom 42% are employed outside Slovenia.

2027 Krka Group business plan

- We plan revenue at €2,308 million, up €129 million or 6% on the 2026 revenue estimate.
- The share of sales generated in markets outside Slovenia is estimated at 94%.
- Region East Europe is expected to generate the highest sales, followed by: Region Central Europe, Region West Europe, Region South-East Europe, Region Slovenia, and Region Overseas Markets.
- We expect prescription pharmaceuticals to remain our leading product category, accounting for more than 83% of total sales.
- Net profit is projected at €474 million, up €35 million or 8% increase on the 2026 estimate.
- We plan to invest €141 million primarily in expansion and modernisation of production facilities and infrastructure, a €26 million increase on 2026.
- The total number of employees in Slovenia and abroad is projected to increase by 2%.

The 2027 business objectives derive from the *2026–2030 Krka Group Development Strategy* and are based on estimates, assessments, forecasts, and other available information. The Management Board believes these forecasts are reasonable. In the event of significant changes in the business environment, such as price erosion, increases in raw material prices, foreign exchange fluctuations in certain key currencies, or a decline in demand for pharmaceutical products, actual operating results may differ from those projected.